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Summary In the late 1990s, the identification of
transporters and transporter-associated genes pro-
gressed substantially due to the development of new
cloning approaches such as expression cloning and,
subsequently, to the implementation of the human
genome project. Since then, the role of many trans-
porter genes in human diseases has been elucidated. In
this overview, we focus on inherited disorders of
epithelial transporters. In particular, we review genetic
defects of the genes encoding glucose transporters
(SLC2 and SLC5 families) and amino acid transporters
(SLC1, SLC3, SLC6 and SLC7 families).
Abbreviations
ABC ATP-binding cassette
ATS arterial tortuosity syndrome
CAT cationic amino acid transporter
EAAT excitatory amino acid transporter
GGM glucose/galactose malabsorption
GLUT glucose transporter
gpaAT glucoprotein-associated amino
acid transporter
HAT heterodimeric amino acid transporter
HGNC HUGO Gene Nomenclature
Committee
H+ V-ATPase vacuolar proton ATPase
IEM inborn error of metabolism
LPI lysinuric protein intolerance
NIS sodium/iodide symporter
PT proximal tubule
rBAT related to b0,+ amino acid transporter
RG renal glucosuria
SGLT sodium/glucose transporter
SLC solute carrier
SIT1 sodium imino acid transporter 1
SNP single nucleotide polymorphism
TM transmembrane
y+LAT1 y+L-type amino acid transporter 1
Introduction
The human genome contains approximately 2000 genes
encoding membrane transporters and transporter-asso-
ciated proteins (Landowski et al 2005). Transporters
are integral proteins that play crucial physiological
roles by participation, for example, in cellular nutrition
and by regulating ionic, osmotic and acid–base homeo-
stasis. They accomplish these important tasks by pro-
moting the cellular or organellar uptake or efflux of
vital substances such as sugars, amino acids, nucleo-
tides, Krebs cycle intermediates, vitamins, organic and
inorganic ions, urea, metals, water and drugs.
Transporters can be divided into three classes:
channels, ATP-dependent transporters and solute car-
rier (SLC) proteins. (1) Channels are pore-forming
structures that allow the passive translocation of ions,
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water or other solutes along their electrochemical
gradients across membranes. Ion channels often include
Fgates_ that can be opened or closed through diverse
gating mechanisms. (2) In higher organisms, ATP-
driven transporters allow the active cellular exit of
solutes. Because these transporters use ATP hydrolysis
as a primary energy source to drive active transport,
they are termed primary-active transporters or pumps.
ATP-binding cassette (ABC) transporters (such as the
MDR multidrug resistance transporters) are ATP-
dependent transporters that mediate the cellular exit
of solutes. (3) The SLC families include the classical
carrier proteins that transport solutes in a passive or
secondary active mode (Hediger et al 2004). These
transporters undergo sequential conformational
changes during the transport cycle. SLC proteins
include facilitated transporters that mediate the diffu-
sion of solutes such as glucose, amino acids and urea
across membranes down their electrochemical gra-
dients (Fig. 1). SLC proteins can also transport more
than one substrate simultaneously, with fixed coupling
stoichiometries. Coupling of the transport of solutes to
the cotransport of Na+ or H+ allows uphill solute
transport against an electrochemical gradient (see
Fig. 1). Such transporters are called secondary-active
transporters. Examples are the intestinal Na+/glucose
cotransporter (SLC5A1) or the intestinal H+-oligopep-
tide transporter (SLC15A1). In general, secondary-
active transporters use the electrochemical gradients
of ions generated by pumps (especially the ubiquitous
Na+,K+-ATPase or the H+ V-ATPase) to maintain
the cellular homeostasis. The SLC proteins also
encode a variety of antiporters or exchangers (trans-
porters of substrates in opposite directions) and multi-
porters (transporters of substrates in both directions,
Fig. 1).
The FHUGOGeneNomenclatureCommittee_ (HGNC;
http://www.genenames.org/) database includes over 45
SLC superfamilies which include a total number of almost
400 transporter genes. A website has been established
(http://www.bioparadigms.org/SLC/menu.asp) that gives
the latest updates on the SLC superfamilies andmembers,
including their roles in human diseases. In general, these
genes are numbered numerically using the root abbrevi-
ation SLC (e.g., SLC1, solute carrier family 1), followed
by the letter FA_ (used solely as a spacer) and the number
of the individual transporter (e.g., SLC1A2 for solute
carrier family 1 member 2). A transporter is assigned to a
specific family if it shows at least 15–25% amino acid
sequence identity with the other members of that family.
Although most of the SLC proteins are now cloned and
functionally well characterized, a number of them are still
Forphans_ because their transport function remains un-
known.
SLC proteins are expressed in the plasma mem-
branes or in membranes of intracellular compartments
such as vesicles, lysosomes and mitochondria. Numer-
ous inherited or acquired human diseases are caused
by SLC protein dysfunction. To this end, the Online
Mendelian Inheritance in Man (OMIM) web site
(http://www.ncbi.nlm.nih.gov/sites/entrez/) lists all of the
human inherited disease found to date and their related
gene mutations SLC-related inborn errors of metabo-
lism (IEMs) can be caused by mutations in the trans-
porter genes themselves or in genes encoding regulatory
components of the transporters such as enzymes or
cytoskeleton proteins (Gamba 2005; Ikeda et al 2006).
There are several molecular mechanisms by which
mutations can alter transporter activities with subse-
quent pathological consequences. Mutations can alter
the membrane expression of transporters through
changes in protein synthesis or protein processing,
Fig. 1 Transport types of the SLC carriers
J Inherit Metab Dis (2008) 31:178–187 179
through altered membrane targeting or membrane
insertion, or through direct changes in the functional
properties of the protein. SLC proteins may also be
involved in polygenic or acquired diseases such as
epilepsy, osteoporosis, nephrolithiasis, diabetes, cancer
and hypertension, for which the precise mechanism of
pathogenesis is still unclear. Genetic approaches such
as the identification of single nucleotide polymor-
phisms (SNPs), genotyping and transgenic strategies
have been helpful in revealing the involvement of SLC
proteins in human physiology and in elucidating their
roles in human diseases. Clinical, molecular and
functional studies are still required to confirm many
of these findings.
Glucose transport
Glucose is essential for cellular metabolism and energy
production. Transporters of glucose and related sugars
are encoded by two SLC gene families: the SLC2
family of facilitated glucose transporters (also called
GLUTs), and the SLC5 family of Na+-coupled glucose
cotransporters (also called SGLTs). Owing to their
importance in human physiology, it is not surprising
that each of these SLC families is associated with
human diseases.
Inborn errors of the SLC2 gene family
The SLC2 family contains 14 members: 12 facilitated
glucose transporters (SLC2A1–12 or GLUT1–12), one
fructose transporter (SLC2A5 or GLUT5) and one
myo-inositol transporter (SLC2A13 or GLUT13).
All SLC2 genes encode transporters possessing 12
membrane-spanning domains, with N- and C-termini
being localized intracellularly. Tissue- and cell-specific
expression of the GLUT homologues underlies their
specific role in the control of whole-body glucose
homeostasis, which is supported by studies with
transgenic mice (Heilig et al 2003). Inherited diseases
are particularly linked to mutations encoding the
GLUT1, GLUT2, GLUT4 and GLUT10 transporters.
In 1985, GLUT1 was the first transporter of this
family to be cloned (Mueckler et al 1985). This protein
is a high-affinity glucose transporter distributed in
almost every tissue, although expression levels vary
within different cell types. For example, GLUT1 is
highly expressed in endothelial cells at the blood–brain
barrier, where it constitutes an important glucose entry
pathway into the brain (Agus et al 1997). The first
defect in an SLC2 transporter was demonstrated by
DeVivo et al (1991), who reported two SLC2A1-
deficient patients with infantile seizures, delayed
development and acquired microcephaly. These symp-
toms are consistent with a defect in glucose transport
across the blood–brain barrier (OMIM 606777 in
Table 1). In 2000, the designation FGLUT1 deficiency
syndrome_ was used for the same disorder observed in
15 children in which heterozygous mutations in the
SLC2A1/GLUT1 gene were found (Wang et al 2000).
This transport disorder has an autosomal dominant
transmission mode. To date, several mutations in the
SLC2A1 gene were found to cause defects in glucose
transport across the blood-brain barrier. Deletions,
insertions, missense or nonsense mutations were iden-
tified in affected patients (Brockmann et al 2001;
DeVivo et al 1991; Klepper et al 2001; Seidner et al
1998; Wang et al 2000). One of them, the p.Gly91Asp
substitution, has been further studied functionally
(Klepper et al 2001). This amino acid exchange affects
a highly conserved cytoplasmic anchor point, the so-
called R-X-G-R-R motif between helices 2 and 3. The
GLUT1 protein expression at the plasma membrane
was unchanged by this mutation, but was functionally
impaired.
The SLC2A2 gene encodes the facilitated glucose
transporter GLUT2. It was isolated from adult human
liver and kidney cDNA libraries and was found to
have 55.5% identity with GLUT1. The encoded
protein is particularly distributed in intestine, kidney,
liver and pancreas: tissues known to have high-capacity
glucose transport systems (Fukumoto et al 1988).
GLUT2 is present in the basolateral membrane of
absorptive epithelial cells where it participates in the
transepithelial transport of glucose, together with the
apical Na+-glucose cotransporters SLC5A1 or SLC5A2
(described below). In hepatocytes, GLUT2 is localized
in the sinusoidal membrane where it controls the
cellular uptake and efflux of glucose into the circula-
tion. In the insulin-producing b-cells of the pancreas,
GLUT2 resides in specific plasma membrane domains
(Orci et al 1989). Functionally, GLUT2 facilitates the
transport of glucose, galactose, mannose and fructose
with low affinity and high capacity.
The defect of this protein is linked to several human
diseases. The first mutation found in the SLC2A2 gene
was an amino acid substitution (p.Val197Ile), present
in the heterozygous state in a patient with non-insulin-
dependent diabetes mellitus (Mueckler et al 1994;
Tanizawa et al 1994). Functional characterization of
this mutation in Xenopus oocytes showed abolition of
GLUT2 transport activity. However, it is still unclear
whether the heterozygosity for this mutation is of
clinical relevance or was just an incidental finding in
this individual. The other known human disease
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caused by a GLUT2 defect is the Fanconi–Bickel
syndrome (OMIM 227810 in Table 1) which is
inherited in an autosomal recessive mode. It is mainly
characterized by hepatorenal glycogen accumulation,
proximal renal tubular dysfunction and impaired
utilization of glucose and galactose (Manz et al 1987).
At least 30 mutations in the SLC2A2 gene have been
reported to be causes of this disease. An interesting
example is presented by a deletion mutation generat-
ing a premature TGA stop codon at position 74
(g.446–449delT, p.Met74X) (Santer et al 1997). It was
found to encode one of the shortest truncated GLUT2
proteins. Some nonsense mutations, substitutions or
splice acceptor sites were also found in different
patients affected with this disease (Akagi et al 2000;
Sakamoto et al 2000; Sanjad et al 1993; Santer et al
1997, 2002).
Another facilitated glucose transporter known to be
linked to a human inherited disease is GLUT10,
encoded by the SLC2A10 gene. This gene was cloned
from a human liver cDNA library (McVie-Wylie et al
2001). GLUT10 is expressed in many human tissues
and organs such as heart, lung, brain, liver, skeletal
muscle, pancreas, placenta, kidney and adipose tissue
(McVie-Wylie et al 2001; Wood et al 2003). GLUT10
was first suggested to be a candidate susceptibility
gene for non-insulin-dependent diabetes mellitus
(McVie-Wylie et al 2001). However, Coucke et al
reported the mapping of the arterial tortuosity syn-
drome (ATS) to the 20q13 locus where SLC2A10 is
located (Coucke et al 2003). ATS is a rare autosomal
recessive connective-tissue disorder, characterized by
widespread arterial involvement with elongation, tor-
tuosity, stenosis and aneurysms of the large and
middle-sized arteries (OMIM 208050 in Table 1). The
pathogenesis of ATS seems to be due to the upregu-
lation of the TGFb signalling pathway (Coucke et al
2006). However, the mechanisms by which mutations
in the SLC2A10 gene lead to TGFb activation are still
unknown.
Inborn errors of the SLC5 gene family
The second family of mammalian glucose transporters
is the FSLC5 Na+/glucose cotransporter family_. The
first reported member of this family is the Na+/glucose
cotransporter 1 (SGLT1) encoded by the SLC5A1
gene. It was identified by expression cloning with
Xenopus oocytes (Hediger et al 1987). There are 11
gene members in this SLC5 family. Most of them
function as Na+-coupled substrate transporters. Trans-
ported substrates include glucose,myo-inositol, mannose,T
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vitamins, monocarboxylates and iodide (Agus et al
1997; Kanai et al 1994; Roll et al 2002; Smanik et al
1997; Srinivas et al 2005; Tazawa et al 2005). SGLT1
mediates secondary active glucose absorption across
brush border membrane of epithelial cells in the
intestine. This function explains the phenotype of the
inherited disease linked to SGLT1 defects, called
glucose/galactose malabsorption (GGM), which is
characterized by diarrhoea and dehydration (see
OMIM 606824 in Table 1). Around 50 mutations were
found in patients with GGM (Lam et al 1999; Martin
et al 1996; Turk et al 1991, 1994). The first mutation
was demonstrated in two sisters with glucose/galactose
malabsorption. It was a G>A transition at nucleotide
92, resulting in an aspartate-to-asparagine substitution
at position 28 in the transporter protein (g.92 G>A,
p.Asp28Asn) (Turk et al 1991). Although missense
mutations can lead to the synthesis of full-length
proteins, these involved in GGM cause defects in
trafficking of the proteins to the plasma membrane
(Turk et al 1993). Another group showed that in 15
patients with missense mutations, the function of
SLC5A1 was directly impaired (Martin et al 1996).
Nonsense or frameshift mutations result in truncated
proteins that are not functional.
The human SLC5A2 (alias SGLT2) was demon-
strated to be a kidney-specific transporter. It functions
as a low-affinity high-capacity Na+-glucose cotrans-
porter (Kanai et al 1994). Detailed localization studies
demonstrated that SGLT2 is expressed in the apical
membranes of S1 and also S2 segments of the proximal
tubule (PT) cells. SGLT2 is responsible for reabsortion
of the bulk of filtered D-glucose. It does not transport
D-galactose. In contrast, intestinal SGLT1 is a high-
affinity low-capacity glucose and galactose transporter.
In the kidney, SGLT1 is expressed in proximal tubule
S3 segments where it reabsorbs any residual glucose
which escaped the S1 and S2 segments. Not too
surprisingly, it was proposed that a defect in the
SGLT2 gene could be involved in the familial form
of renal glucosuria (RG; OMIM 233100 in Table 1).
The clinical symptoms of this autosomal recessive
disorder are substantial daily loss of glucose, despite
a normal glucose tolerance test. To date, about 26
mutations have been described in patients with RG. In
2002, homozygosity for a nonsense mutation was
demonstrated in a patient with RG (van den Heuvel
et al 2002). Moreover, other truncating mutations were
found in the SLC5A2 gene in patients with RG
(Calado et al 2004). Extensive analysis of RG patients
by Santer and collaborators confirmed the important
role of the SCL5A2 glucose transporter in renal
tubular glucose reabsorption (Santer et al 2003).
The human sodium/iodide symporter (NIS) which
also transports other monovalent anions, is encoded by
the fifth member of the SLC5 transporter group
(Smanik et al 1996). The primary function of this
transporter is to take up Ij from blood across the
basolateral membrane of the thyroid follicular cells in
order to secrete Ij through the SLC26A4 anion
exchanger into the follicular lumen, wherein organifi-
cation of Ij occurs that is necessary for the synthesis of
the T3 and T4 thyroid hormones. The NIS transporter
is also expressed in colon, breast and ovary (Smanik
et al 1996, 1997). Studies on the regulation of the NIS
gene revealed that the NIS gene expression is tightly
controlled by the thyroid-stimulating hormone and the
thyroid transcription factor and that DNA methylation
plays a role in loss of SLC5A5 gene expression in
thyroid carcinomas (Ohmori et al 1998; Venkataraman
et al 1999). SLC5A5 gene expression appears to play a
key role in thyroid gland function. As expected, the
first mutation in the NIS gene was found in a patient
with an iodide transport defect in the synthesis of
thyroid hormones (OMIM 274400 in Table 1). This
defect is characterized by an inability of the thyroid to
maintain a concentration difference of iodide between
the plasma and the thyroid gland. Symptoms of this
patient were mild goitre and multiple mass lesions in
lobes of the thyroid. The mutation identified was a
single A>C transversion which replaced threonine by
proline at position 354 (c.1060A>C, p.Thr354Pro)
(Fujiwara 1997). To date, eight different mutations
were found in patients with thyroid hormogenesis
defects, including 5 missense mutations, 2 nonsense
mutations and 1 deletion mutation (Kosugi et al 1998,
1999, 2002; Pohlenz et al 1998). These mutations are
believed to decrease the SLC5A5 transport activity at
the plasma membrane.
Amino acid transport
Amino acids are required for protein synthesis and
they also represent an important source of nitrogen.
Some amino acids are considered essential, because
cells cannot synthesize them. The liver is the major
site of nitrogen metabolism in the body. Amino acids
can be divided into three families: those that are
glucogenic, those that are ketogenic or those that are
both. Amino acids are precursors of the formation of
glucose or acetyl-CoA and these two products are
essential for ATP production by the Krebs cycle.
Another very important role for amino acids is their
function as neurotransmitters such as glutamate,
aspartate and g-aminobutyrate. The amino acids
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glutamate and aspartate are excitatory neurotransmit-
ters which are released at glutamatergic synapses of
the mammalian central nervous system. An accumu-
lation of extracellular excitatory amino acids can be
excitotoxic.
The following SLC gene families are associated with
amino acid transporter disorders: the SLC1 family
encoding glutamate and neutral amino acid trans-
porters, the SLC3 family encoding the heavy subunits
of heteromeric amino acid transporters, the SLC6
family encoding Na+- and Clj-dependent neurotrans-
mitter transporters, the SLC7 family encoding the
cationic amino acid/glycoprotein-associated amino acid
transporters, and the SLC25 family encoding mito-
chondrial transporters.
Inborn errors of the SLC1 gene family
The SLC1 family consists of seven transporters.
Several of these transporters are expressed both in
epithelial tissues and in neurons or glial cells of the
central nervous system: five high-affinity glutamate
transporters and two neutral amino acid transporters.
The glutamate transporters mediate the transport of
L-Glu, L-Asp and D-Asp, accompanied by the co-
transport of Na+ and H+ and the countertransport of
K+. Themembrane topologymodel of these transporters
shows special features in that the central domain
possesses 8 transmembrane (TM) segments and 3 re-
entrant loops, with both amino- and carboxyl-termini
in the cytosol (Grunewald and Kanner 2000; Torres
and Amara 2007). Because of the importance of these
transporters in neurotransmission, genetic diseases asso-
ciated with their dysfunction are expected to be rare.
Nevertheless, a heterozygous mutation (g.1047C>G,
p.Pro290Arg) in the SLC1A3 gene (alias excitatory
amino acid transporter 1 or EAAT1) was found in only
a single patient with episodic ataxia, seizures, migraine,
and alternating hemiplegia (Jen et al 2005). This
mutation was not present in the patient_s asymptomatic
parents, suggesting that it arose de novo. Functional
studies showed that the missense substitution leads to
decrease of both glutamate uptake and EAAT1 expres-
sion to plasmamembrane, which contributes to neuronal
hyperexcitability in the patient (Jen et al 2005). Howev-
er, no further information is known about this mutation
and its clinical relevance.
Inborn errors of the SLC3 gene family
The family of SLC3 genes consists of two genes, rBAT
and 4F2hc, encoding proteins with one single trans-
membrane domain: a large extracellular glycosylated
C-terminus and a short intracellular N-terminus (type
II membrane glycoproteins). The proteins of the SLC3
family form the so-called heavy subunits of hetero-
meric amino acid transporters (HATs). In these trans-
porters, the light subunits, which are members of the
SLC7 family (described below), form the actual
transporter unit (Wagner et al 2001).
By expression cloning using Xenopus oocytes,
rBAT (related to b0,+ amino acid transporter) cDNA
was identified, which is named SLC3A1. rBAT is
expressed in the apical plasma membrane of epithelial
cells in kidney and small intestine where it is involved
in transport of cystine and dibasic and neutral amino
acids (Palacin and Kanai 2004; Wells et al 1992).
Cystinuria is characterized by cystine precipitation
inducing the formation of calculi in the urinary tract,
which leads to obstruction, infection and finally renal
insufficiency (OMIM 220100 in Table 2). Cystinuria is
a rare disorder which has an autosomal recessive trans-
mission mode (Calonge et al 1995; Garrod and Hurtley
1906; Palacin et al 2001). In general, the excretion of
both cystine and dibasic amino acids is increased in the
urine in patients with cystinuria.
Mutations in the SLC3A1 and SLC7A9 genes are
responsible for the disease. The disease can be divided
into phenotype A (normal amino aciduria in heterozy-
gotes) and phenotype B (moderate to high hyperexcretion
of cystine and dibasic amino acids in heterozygotes).
Cystinuria type A is caused by mutations in the SLC3A1
gene, whereas mutations in the SLC7A9 gene cause
cystinuria type B, in addition to some cases of cystinuria
Ftype I_ (Calonge et al 1994, 1995; Dello Strologo et al
2002). In 2002, Dello Strologo et al suggested that this
classification system should be replaced by a new one:
type A due to mutations in the SLC3A1 gene, type B
due to mutations in the SLC7A9 gene, and type A/B
due to mutations in both the SLC3A1 and SLC7A9
genes (Dello Strologo et al 2002). To date, more than 60
mutations in the SLC3A1 gene have been identified,
mostly missense mutations (Palacin et al 2001).
Inborn errors of the SLC7 gene family
The SLC7 family corresponds to the cationic amino
acid transporters (CAT). They also include the glyco-
protein-associated amino acid transporters (gpaAT).
The SLC7 family contains 11 genes. This family can be
further divided into two functional subgroups, the
CAT group (SLC7A1–4) and the gpaAT group
(SLC7A5–11), also called light chains of the hetero-
dimeric amino acid transporters HAT (see above)
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(Deves et al 1998; Kim et al 1991). In general, CATs
function as facilitated transporters, whereas gpaATs
mostly function as obligatory exchangers. They also
largely differ in their predicted structure, in that the
CATs have 14 putative TM segments and are glycosy-
lated, whereas the gpaATs have 12 TM domains, are
not glycosylated and need to associate with a glyco-
protein of the SLC3 superfamily (4F2hc or rBAT) for
surface expression.
Two gpaAT genes were identified as linked to human
inherited disease. The first is SLC7A7 and encodes
the y+L-type amino acid transporter 1 (y+LAT1) which
has been shown to mediate preferentially the ex-
change of cytosolic cationic amino acid for extracellu-
lar neutral amino acid (Torrents et al 1998). The causal
gene in lysinuric protein intolerance (LPI; see OMIM
222700 in Table 2) was mapped to the locus 14q11.2
corresponding to the same chromosomal region as the
SLC7A7 gene. These results strongly suggest that
dysfunction of y+LAT1 is a cause of LPI. Indeed, a
defect in the plasma membrane transport of dibasic
amino acids was demonstrated at the basolateral
membrane of renal tubule epithelial cells, in small
intestine and in skin fibroblasts from patients with
LPI. LPI is a rare autosomal recessive disease and
symptoms of LPI were described as severe mental re-
tardation, physical retardation, mild intestinal malab-
sorption syndrome and increase in urinary excretion of
lysine, ornithine and arginine (Oyanagi et al 1970).
Mutated SLC7A7 proteins were initially found in 31
Finnish patients and 1 Spanish patient with LPI. The
Finnish patients were homozygous for a missense muta-
tion leading to a premature stop codon (g.1181A>T,
p.Phe308X). This mutation abolishes an acceptor AG
splice site at the end of the intron and leads to cryptic
splicing at the next AG site, 10 bp downstream. The
Spanish patient was a compound heterozygote with a
frameshift mutation (g.1291delCTTT) in one allele and a
missense mutation (g.1287T>G, p.Lys334Arg) on the
other allele (Torrents et al 1999). To date, about 20
mutations were found in the SLC7A7 gene of patients
with LPI.
The other SLC7 gene linked to an inherited disease
is SLC7A9 encoding the b0,+ amino acid transporter.
This transporter was found to be expressed in kidney,
liver, small intestine and placenta where, in contrast to
SLC7A7, it mediates preferentially the exchange of
extracellular cationic amino acids for intracellular
neutral amino acids (Feliubadalo et al 1999). As noted
above, mutations in this gene were shown to be linked
to cystinuria type B. Numerous mutations in the
SLC7A9 gene were found in patients with cystinuria
(Font et al 2001).T
a
b
le
2
In
b
o
rn
e
rr
o
rs
o
f
a
m
in
o
a
ci
d
m
e
ta
b
o
li
sm
ca
u
se
d
b
y
fa
u
lt
y
ce
ll
su
rf
a
ce
S
L
C
s
S
L
C
m
e
m
b
e
r,
D
T
T
:
su
b
st
ra
te
s
O
M
IM
n
o
.
D
is
e
a
se
n
a
m
e
C
li
n
ic
a
l,
m
o
le
cu
la
r
a
n
d
b
io
lo
g
ic
a
l
fe
a
tu
re
s
IM
L
o
cu
s
S
L
C
1
A
3
,
M
:
N
a
+
,
H
+
,
g
lu
ta
m
a
te
/K
+
6
0
0
1
1
1
E
p
is
o
d
ic
a
ta
x
ia
,
ty
p
e
6
E
p
is
o
d
ic
a
ta
x
ia
,
se
iz
u
re
,
m
ig
ra
in
e
,
a
lt
e
rn
a
ti
n
g
h
e
m
ip
le
g
ia
–
5
p
1
3
S
L
C
3
A
1
,
E
:
cy
st
in
e/
d
ib
as
ic
am
in
o
ac
id
2
2
0
1
0
0
C
y
st
in
u
ri
a
,
ty
p
e
A
In
cr
e
a
se
d
e
x
cr
e
ti
o
n
o
f
cy
st
in
e
a
n
d
d
ib
a
si
c
a
m
in
o
a
ci
d
s;
fo
rm
a
ti
o
n
o
f
cy
st
in
e
ca
lc
u
li
R
2
p
1
6
.3
S
L
C
6
A
1
9
,
C
:
N
a
+
/n
e
u
tr
a
l
a
m
in
o
a
ci
d
2
3
4
5
0
0
H
a
rt
n
u
p
d
is
o
rd
e
r
P
e
ll
a
g
ra
-l
ik
e
li
g
h
t-
se
n
si
ti
v
e
ra
sh
,
ce
re
b
e
ll
a
r
a
ta
x
ia
,
e
m
o
ti
o
n
a
l
in
st
a
b
il
it
y
,
a
n
d
a
m
in
o
a
ci
d
u
ri
a
R
5
p
1
5
S
L
C
7
A
7
,
E
:c
at
io
n
ic
/n
eu
tr
al
am
in
o
ac
id
2
2
2
7
0
0
L
y
si
n
u
ri
c
p
ro
te
in
in
to
le
ra
n
ce
S
e
v
e
re
m
e
n
ta
l
re
ta
rd
a
ti
o
n
,
p
h
y
si
ca
l
re
ta
rd
a
ti
o
n
,
m
il
d
in
te
st
in
a
l
m
a
la
b
so
rp
ti
o
n
sy
n
d
ro
m
e
,
in
cr
e
a
se
d
u
ri
n
a
ry
e
x
cr
e
ti
o
n
o
f
ly
si
n
e
,
o
rn
it
h
in
e
a
n
d
a
rg
in
in
e
R
1
4
q
1
1
.2
S
L
C
7
A
9
,
E
:
cy
st
in
e
/d
ib
a
si
c
a
m
in
o
a
ci
d
2
2
0
1
0
0
C
y
st
in
u
ri
a
,
ty
p
e
B
C
y
st
in
e
p
re
ci
p
it
a
ti
o
n
,
fo
rm
a
ti
o
n
o
f
ca
lc
u
li
in
th
e
u
ri
n
a
ry
tr
a
ct
,
re
n
a
l
in
su
ff
ic
ie
n
cy
R
1
9
q
1
3
.1
S
L
C
2
5
A
2
2
M
:
g
lu
ta
m
a
te
/H
+
o
r
O
H
j
6
0
9
3
0
4
N
e
o
n
a
ta
l
m
y
o
cl
o
n
ic
e
p
il
e
p
sy
w
it
h
su
p
p
re
ss
io
n
-b
u
rs
t
p
a
tt
e
rn
In
tr
a
ct
a
b
le
e
p
il
e
p
ti
c
sy
n
d
ro
m
e
s
w
it
h
e
it
h
e
r
n
e
o
n
a
ta
l
o
n
se
t
o
r
o
n
se
t
d
u
ri
n
g
th
e
fi
rs
t
m
o
n
th
s
o
f
li
fe
,
a
n
d
n
e
o
n
a
ta
l
h
y
p
o
to
n
ia
.
C
h
a
ra
ct
e
ri
ze
d
b
y
a
ty
p
ic
a
l
e
le
ct
ro
e
n
ce
p
h
a
lo
g
ra
m
p
a
tt
e
rn
—
n
a
m
e
ly
,
su
p
p
re
ss
io
n
b
u
rs
t,
in
w
h
ic
h
h
ig
h
e
r-
v
o
lt
a
g
e
b
u
rs
ts
o
f
sl
o
w
w
a
v
e
s
m
ix
e
d
w
it
h
m
u
lt
if
o
ca
l
sp
ik
e
s
a
lt
e
rn
a
te
w
it
h
is
o
e
le
ct
ri
c
su
p
p
re
ss
io
n
p
h
a
se
s.
B
ra
in
a
tr
o
p
h
y
a
n
d
a
b
n
o
rm
a
l
v
is
u
a
l
n
e
rv
e
-c
o
n
d
u
ct
io
n
v
e
lo
ci
ty
h
a
v
e
b
e
e
n
a
ls
o
o
b
se
rv
e
d
.
R
1
1
p
1
5
.5
D
T
T
=
d
e
fe
ct
iv
e
tr
a
n
sp
o
rt
ty
p
e
;
M
=
m
u
lt
ip
o
rt
e
r;
C
=
co
tr
a
n
sp
o
rt
e
r;
E
=
e
x
ch
a
n
g
e
r;
IM
=
in
h
e
ri
ta
n
ce
m
o
d
e
;
R
=
a
u
to
so
m
a
l
re
ce
ss
iv
e
;
D
=
a
u
to
so
m
a
l
d
o
m
in
a
n
t.
184 J Inherit Metab Dis (2008) 31:178–187
Inborn errors of the SLC6 gene family
Transporters of the SLC6 gene family belong to the
sodium- and chloride-dependent neurotransmitter
transporter family which includes 20 members. These
genes encode proteins having probably 12 transmem-
brane domains. Among family members are trans-
porters of neurotransmitters, osmolytes and creatine.
Other members correspond to the previously de-
scribed classical Na+-dependent amino acid uptake
systems.
Several members of the SLC6 family are linked to
inherited diseases. Many are associated with primarily
neurological disorders and are therefore not discussed
further in this overview. Defects of SLC6A19 are
related to a type of amino aciduria. This gene encodes
the system B0 transporter, called B0 AT1. High levels
of expression of SLC6A19 were found in the apical
membrane of renal and small intestinal epithelial cells.
Functional studies in Xenopus oocytes showed that the
SLC6A19-mediated transport is electrogenic and Na+-
and pH-dependent, and that, in contrast to other ana-
logues of the SLC6 superfamily, it is Clj-independent
(Broer et al 2004; Kleta et al 2004). Using homozygosity
mapping, Kleta and collaborators confirmed that the
causative gene in the Hartnup disorder is located on
locus 5p15 and corresponds to SLC6A19 (Kleta et al
2004). This disorder is an autosomal recessive disorder
which is characterized by a pellagra-like light-sensitive
rash, cerebellar ataxia, emotional instability, and amino
aciduria (OMIM 234500 in Table 2). Ten different
mutations have been described to date causing this
disease. One mutation, the p.Asp173Asn allele, is
present in 42% ofHartnup chromosomes from unrelated
families from Australia and North America (Azmanov
et al 2007). These mutations apparently reduce the
transport function of neutral amino acids across epithe-
lial cells in renal proximal tubules and intestinal mucosa.
Iminoglycinuria is a rare autosomal recessive disorder
characterized by increased urinary excretion of proline,
hydroxyproline and glycine, resulting in neurosensory
hearing loss and ichthyosis, whichmay be associatedwith
mental retardation (Goyer et al 1968; Swarna et al 2004).
Iminoglycinuria has been suggested to be caused by
defects of renal tubule amino acid transporters. The
gene product of SLC6A20 (also known as sodium imino
acid transporter 1 or SIT1) has been characterized
recently (Takanaga et al 2005). Its functional properties
were shown to correspond to those of the classical
system IMINO which mediates Na+-dependent proline
uptake into epithelial cells of kidney and intestine. It is
tempting to speculate that mutations in the SLC6A20
gene are the cause of some cases of hereditary
iminoaciduria. However, the precise genetic defects of
this disease have not yet been elucidated.
Inborn errors of the SLC25 gene family
Members of the SLC25 family of mitochondrial
carriers also transport amino acids, and defects of
their genes can be involved in such human pathologies
as seizures. One example has been described recently
and concerns defects of the SLC25A22 gene, which
encodes a ubiquitous glutamate multiporter (transport
of l-glutamate either with H+ or in exchange for OHj;
see Fig. 1) (Fiermonte et al 2002). Molinari and
colleagues found the SLC25A22 gene within the
interval on 11p15.5 linked to neonatal myoclonic epi-
lepsy with suppression-burst pattern (OMIM 609304 in
Table 2). This inherited disease has an autosomal
recessive transmission mode and is principally charac-
terized by early-onset severe seizures and neonatal
hypotonia. In the same work, Molinari and colleagues
reported the identification of a homozygous missense
mutation in the SLC25A22 gene (p.Pro206Leu) which
causes impaired mitochondrial glutamate transport
and consequently seizures in the affected children
(Molinari et al 2005).
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